

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1644PNH

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Jan 25 BLAST(P) searching in REGISTRY available in STN on the Web  
NEWS 3 Jan 29 FSTA has been reloaded and moves to weekly updates  
NEWS 4 Feb 01 DELILIT now produced by FI3 Karlsruhe and has a new update  
frequency  
NEWS 5 Feb 12 Access via Tymnet and SprintNet Eliminated Effective 3/31/02  
NEWS 6 Mar 08 Gene Names now available in BIOSIS  
NEWS 7 Mar 22 TOXLIT no longer available  
NEWS 8 Mar 22 TROTHERMO no longer available  
NEWS 9 Mar 28 US Provisional Priorities searched with P in CA/CAPLUS  
and USEPATFULL  
NEWS 10 Mar 28 LIPINSKI/CALC added for property searching in REGISTRY  
NEWS 11 Apr 02 PAPEFCHEM no longer available on STN. Use PAPEFCHEM2 instead.  
NEWS 12 Apr 02 "Ask CAS" for self-help around the clock  
NEWS 13 Apr 02 BEILSTEIN: Reload and Implementation of a New Subject Area  
NEWS 14 Apr 02 CDE will be removed from STN  
NEWS 15 Apr 12 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB  
NEWS 16 Apr 22 Records from ISI.com available in CAPLUS, HCAPLUS, and ZCAPLUS  
NEWS 17 Apr 22 BIOSIS Gene Names now available in TOXCENTER  
NEWS 18 Apr 22 Federal Research in Progress (FEDRIP) now available  
NEWS 19 Jun 02 New e-mail delivery for search results now available  
NEWS 20 Jun 12 MEDLINE Reload  
NEWS 21 Jun 12 ECTEULL has been reloaded  
NEWS 22 Jul 01 FORGE no longer contains STANDARDS file segment  
NEWS 23 Jul 12 NTIS to be reloaded July 28, 2002  
  
NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,  
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),  
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:56:10 ON 20 JUL 2002

=> file medline embase biosis scisearch caplus  
COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 12:56:24 ON 20 JUL 2002

FILE 'EMBASE' ENTERED AT 12:56:24 ON 20 JUL 2002  
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 12:56:24 ON 20 JUL 2002  
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'SCISEARCH' ENTERED AT 12:56:24 ON 20 JUL 2002  
COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'CAPLUS' ENTERED AT 12:56:24 ON 20 JUL 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s airway hyperresponsiveness  
L1 5892 AIRWAY HYPERRESPONSIVENESS

=> s l1 and inhibitor  
L1 1246 L1 AND INHIBITOR

=> s l1 and calcitonin gene related peptide receptor  
L3 1 L2 AND CALCITONIN GENE RELATED PEPTIDE RECEPTOR

=> d l1 click aks

L3 ANSWER 1 IF 1 CAPLUS COPYRIGHT 2002 ACS  
2401:093112 Document No. 119:236441 Role of calcitonin gene-related peptide  
CGRP for reducing allergen-induced **airway**  
**hyperresponsiveness**. Gelfand, Erwin W.; Dakhama, Azzeddine  
National Jewish Medical and Research Center, USA). PCT Int. Appl. WO  
2001093112 A1 2001-09-21, 62 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT,  
AU, AC, BA, BB, BG, BR, BY, BC, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ,  
EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP,  
KR, KZ, LT, LK, LR, LS, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO,  
NC, NL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,  
US, VN, YU, ZA, ZW, AM, AC, BY, EG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF,  
BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LJ,  
MG, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2.  
APPLICATION: WO 2001-093112 20010914. PRIORITY: US 2000-PV189622  
20000914.

AB Disclosed is a method to reduce **airway**  
**hyperresponsiveness**, such as allergen-induced **airway**  
**hyperresponsiveness**, in a mammal by administering an agent that  
increases the k<sub>cat</sub> activity of a CGRP receptor. The agent administered  
to a mammal is an antibody in conjunction with another agents selected  
from the group consisting of corticosteroids, (oral, inhaled and  
injected), (beta<sub>2</sub>-agonists (long and short acting), leukotriene modifiers  
**inhibitors** or receptor antagonists), antihistamines,  
phosphodiesterase **inhibitors**, sodium cromoglycate, nedocrilal,  
theophylline and CGRP. Also disclosed are methods for identifying compds.  
useful in the present method.

=> d his

FILE 'HOME' ENTERED AT 12:56:10 CN 20 JUL 2002)

FILE 'MELLINE, EMEASE, BIOSIS, SCISEARCH, CAPLUS' ENTERED AT 12:56:24 CN  
20 JUL 2002

L1 8882 S AIRWAY HYPERRESPONSIVENESS  
L2 1246 S L1 AND INHIBITOR  
L3 1 S L2 AND CALCITONIN GENE RELATED PEPTIDE RECEPTOR

=> s 12 and "CGRP" antagonist

L4 9 L2 AND "CGRP" ANTAGONIST

=> s 12 and "CGRP receptor"

L5 1 L2 AND "CGRP RECEPTOR"

=> d 15 chick abs

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS

2801:683112 Document No. 135:236441 Role of calcitonin gene-related peptide  
(CGRP) for reducing allergen-induced **airway**

**hyperresponsiveness.** Gelfand, Erwin W.; Dakhama, Azzeddine

(National Jewish Medical and Research Center, USA). PCT Int. Appl. WO  
2001068119 A1 20010920, 69 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT,  
AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ,  
EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP,  
KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO,  
NC, NL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TC, TM, TR, TT, TZ, UA, UG,  
US, VN, YU, ZA, ZW, AM, AC, BY, KG, KZ, MD, RU, TC, TM; RW: AT, BE, BF,  
BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU,  
MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2.  
APPLICATION: WO 2001-US8204 20010314. PRIORITY: US 2000-PV139622  
20000314.

AB Disclosed is a method to reduce **airway**

**hyperresponsiveness**, such as allergen-induced **airway**

**hyperresponsiveness**, in a mammal by administering an agent that

increases the hist. activity of a **CGRP receptor**. The

agent administered to a mammal is an antibody in conjunction with another  
agents selected from the group consisting of corticosteroids, (oral,  
inhaled and injected), .beta.-agonists (long and short acting),  
leukotriene modifiers (**inhibitors** or receptor antagonists),  
antihistamines, phosphodiesterase **inhibitors**, sodium  
chromoglycate, nedocromil, theophylline and CGRP. Also disclosed are  
methods for identifying compds. useful in the present method.

=> s (Gelfand a?/au or dakhama a?/au)

L6 2916 GELFAND B?/AU OR DAKHAMA A?/AU

=> s 16 and airway hyperresponsiveness

L7 265 L6 AND AIRWAY HYPERRESPONSIVENESS

=> dup remove 17

PROCESSING COMPLETED FOR L7

L7 99 DUP REMOVE L7 (166 DUPLICATES REMOVED)

=> s 18 and calcitonin gene related peptide

L8 2 L8 AND CALCITONIN GENE RELATED PEPTIDE

=> dup remove 19

PROCESSING COMPLETED FOR L9

L9 2 DUP REMOVE L9 (1 DUPLICATES REMOVED)

=> d 110 1-2 ckib aks

L10 ANSWER 1 OF 2 MEDLINE  
2002219008 Document Number: 21951265. PubMed ID: 11956058. Regulation of  
**airway hyperresponsiveness by calcitonin  
gene-related peptide** in allergen sensitized  
and challenged mice. **Dakhama Azzeddine**; Kanehiro Akihiko; Makela  
Mika J; Loader Joan E; Larsen Gary L; **Gelfand Erwin W.** (Division  
of Cell Biology and Pulmonary Medicine, Department of Pediatrics, National  
Jewish Medical and Research Center, Denver, Colorado 80206, USA. )  
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, (2002 Apr 15)  
165 (3) 1137-44. Journal code: 0421-6742. ISSN: 1073-449X. Pub. country:  
United States. Language: English.

AB Sensory neuropeptides are localized to airway nerves and endocrine cells  
in both human and animal species and may participate in the development of  
airway inflammation and hyperresponsiveness (AHR). We used a mouse model  
to identify the changes that occur in **calcitonin gene-  
related peptide** (CGRP) expression in the airways during  
development of allergic inflammation and to investigate the potential role  
of this neuropeptide in modulating AHR. In sensitized mice, allergen  
challenge induced eosinophilic airway inflammation and AHR and resulted in  
considerable depletion of CGRP in neuroepithelial bodies and submucosal  
nerve plexuses without altering the overall density of airway nerve  
fibers. This depletion was subsequent to the development of airway  
inflammation and was prevented by anti-very late antigen-4 and  
anti-interleukin-5 treatments, which blocked airway eosinophilia and  
abolished AHR. Administration of CGRP to sensitized and challenged mice  
resulted in the normalization of airway responsiveness to inhaled  
methacholine, an effect that was neutralized by the receptor antagonist  
CGRP(6-37). These data demonstrate that replacement of CGRP following its  
depletion in allergic mice can reverse the changes in airway  
responsiveness and suggest that CGRP may have potential for the treatment  
of allergic AHR.

L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2002 ACS  
2001:693112 Document No. 135:136441 Role of **calcitonin  
gene-related peptide** (CGRP) for reducing  
allergen-induced **airway hyperresponsiveness**.  
**Gelfand, Erwin W.**; **Dakhama, Azzeddine** (National Jewish  
Medical and Research Center, USA). PCT Int. Appl. WO 2001068118 A1  
20010910, 69 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA,  
BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI,  
GB, GE, GR, GU, HK, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NO, NZ, PL, PT,  
RO, RU, SD, SE, SG, SI, SK, SL, TH, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,  
ZA, ZW, AM, AZ, BY, EG, GZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG,  
CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MG, ML, MR,  
NE, NL, PT, SE, SN, TD, TG, TR. English). CODEN: PIXXD2. APPLICATION:  
WO 2001-US8244 20010314. PRIORITY: US 2000-PV189622 20000314.

AB Disclosed is a method to reduce **airway  
hyperresponsiveness**, such as allergen-induced **airway  
hyperresponsiveness**, in a mammal by administering an agent that  
increases the biol. activity of a CGRP receptor. The agent administered  
to a mammal is an antibody in conjunction with another agents selected  
from the group consisting of corticosteroids, (oral, inhaled and  
injected), beta-agonists (long and short acting), leukotriene modifiers  
(inhibitors or receptor antagonists), antihistamines, phosphodiesterase  
inhibitors, sodium cromoglycate, nedocromil, theophylline and CGRP. Also  
disclosed are methods for identifying compds. useful in the present  
method.

=> s "CGRP"

L11 23371 "CGRP"

=> s 111 and lung

L12 1013 L11 AND LUNG

=> s 112 and "AHR"

L13 5 L12 AND "AHR"

=> dup remove 113

PROCESSING COMPLETED FOR L13

L14 2 DUF REMOVE L13 (3 DUPLICATES REMOVED)

=> d 114 1-1 skip abs

L14 ANSWER 1 OF 1 MEDLINE

2002219003 Document Number: 21952265. PubMed ID: 11956058. Regulation of airway hyperresponsiveness by calcitonin gene-related peptide in allergen sensitized and challenged mice. Dakhama Azzeddine; Kanehiro Arihiko; Makela Mika J; Loader Joan E; Larsen Gary L; Gelfand Erwin W. (Division of Cell Biology and Pulmonary Medicine, Department of Pediatrics, National Jewish Medical and Research Center, Denver, Colorado 80266, USA. ) AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, (2002 Apr 15) 165 (8 1137-44. Journal code: 9421642. ISSN: 1073-449X. Pub. country: United States. Language: English.

AB Sensory neuropeptides are localized to airway nerves and endocrine cells in both human and animal species and may participate in the development of airway inflammation and hyperresponsiveness (AHR). We used a mouse model to identify the changes that occur in calcitonin gene-related peptide (CGRP) expression in the airways during development of allergic inflammation and to investigate the potential role of this neuropeptide in modulating AHR. In sensitized mice, allergen challenge induced eosinophilic airway inflammation and AHR and resulted in considerable depletion of CGRP in neuroepithelial bodies and submucosal nerve plexuses without altering the overall density of airway nerve fibers. This depletion was subsequent to the development of airway inflammation and was prevented by anti-very late antigen-4 and anti-interleukin-5 treatments, which blocked airway eosinophilia and abolished AHR. Administration of CGRP to sensitized and challenged mice resulted in the normalization of airway responsiveness to inhaled methacholine, an effect that was neutralized by the receptor antagonist CGRP(8-37). These data demonstrate that replacement of CGRP following its depletion in allergic mice can reverse the changes in airway responsiveness and suggest that CGRP may have potential for the treatment of allergic AHR.

L14 ANSWER 1 OF 1 MEDLINE DUPLICATE 1

2001540889 Document Number: 21471662. PubMed ID: 11581007. Chronic smoking enhances tachykinin synthesis and airway responsiveness in guinea pigs. Kwong K; Wu Z X; Kaskan M L; Krajnak K M; Wise P M; Lee L Y. (Department of Physiology, University of Kentucky, Lexington, Kentucky 40536, USA. ) AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, (2001 Sep) 25 (3) 299-305. Journal code: 8917225. ISSN: 1044-1549. Pub. country: United States. Language: English.

AB This study tests the hypothesis that the bronchial hyperreactivity induced by chronic cigarette smoke (CS) exposure involves the increased expression and release of tachykinins and calcitonin gene-related peptide (CGRP) from afferent nerve fibers innervating the airways. In guinea pigs chronically exposed to CS (10 min twice daily for 14-17 d), peak response in total lung resistance to capsaicin (1.68 microg/kg, intravenously) was significantly greater than that evoked by the same dose of capsaicin in control (air-exposed) animals. This augmented response in CS-exposed animals was abolished after treatment with CP-99994 and SR-49969, the neurokinin NK1 and NK2 receptor

antagonists, suggesting the involvement of tachykinins in chronic CS-induced airway hyperresponsiveness (AHR). Further, substance P (SP)-like immunoreactivity (LI) and CGRP-LI in the airway tissue were significantly greater in the CS animals than in the control animals. Finally, beta-preprotachykinin (PPT, a splice variant from the PPT A gene encoding tachykinins including SP and NKA) messenger RNA levels as measured by in situ hybridization histochemistry displayed a significant increase in jugular ganglion neurons but not in dorsal root or nodose ganglion neurons. These data suggest that chronic CS-induced AHR is related to an increase in SP synthesis and release in jugular ganglion neurons innervating the lungs and airways.

=> d his

(FILE 'HOME' ENTERED AT 12:56:10 ON 20 JUL 2002)

FILE 'MEDLINE, EMBASE, BIOSIS, SCISEARCH, CAPLUS' ENTERED AT 12:56:24 ON 20 JUL 2002

L1 3882 S AIRWAY HYPERRESPONSIVENESS  
 L2 1246 S L1 AND INHIBITOR  
 L3 1 S L2 AND CALCITONIN GENE RELATED PEPTIDE RECEPTOR  
 L4 0 S L3 AND "CGRP" ANTAGONIST  
 L5 1 S L1 AND "CGRP RECEPTOR"  
 L6 2916 S (GELFAND E?, AU OR DAKHAYA A?(AU)  
 L7 269 S L6 AND AIRWAY HYPERRESPONSIVENESS  
 L8 99 DUP REMOVE L7 (106 DUPLICATES REMOVED)  
 L9 1 S L8 AND CALCITONIN GENE RELATED PEPTIDE  
 L10 1 DUP REMOVE L9 (0 DUPLICATES REMOVED)  
 L11 23371 S "CGRP"  
 L12 1029 S L11 AND LUNG  
 L13 1 S L12 AND "AHR"  
 L14 1 DUP REMOVE L13 (0 DUPLICATES REMOVED)

=> s l11 and treatment

L15 2798 L11 AND TREATMENT

=> s l15 and allergy

L16 12 L15 AND ALLERGY

=> dup remove l16

PROCESSING COMPLETED FOR L16

L17 10 DUP REMOVE L16 (2 DUPLICATES REMOVED)

=> d l17 1-10 skip aks

L17 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2002 ACS

2.00:388522 Document No. 133:388703 Nucleic acid encoding a bovine calcitonin receptor-like receptor (BECRLR). Aiyar, Nammi V.; Disa, Jyoti (Smithkline Beecham Corporation, USA). U.S. US 6074848 A 20000613, 16 pp. (English). CODEN: NSXEAM. APPLICATION: US 1999-233796 19990128.

AB BECRLR polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing BECRLR polypeptides and polynucleotides in screening assays to discover compds. that either agonize or antagonize the biol. activity of the receptor. Such compds. are expected to be useful in **treatment** of human diseases, including, but not limited to: infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; diabetes; obesity; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; stroke; ulcers; asthma; **allergies**; benign prostatic hypertrophy; migraine; vomiting;

psychotic and neurol. disorders, including anxiety, schizophrenia, manic depression, depression, delirium, dementia, and severe mental retardation; and dyskinesias, such as Huntington's disease or Gilles de la Tourette syndrome.

L17 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2002 ACS

1999:021267 Document No. 131:253023 Method for counteracting vasospasms, ischemia, renal failure, and treating male impotence using calcitonin gene related peptide. Wimalawansa, Sunil J. (USA). U.S. US 5958877 A 19990928, 9 pp. (English). CODEN: USXXAM. APPLICATION: US 1995-446929 19950518.

AB The present invention provides a method for counteracting pathol. vasospasms or ischemia in target arteries (coronary, carotid, and renal arteries), where the vasospasms or ischemia are due to angioplasty, vascular graft, stent insertion, or arterial surgery by administering calcitonin gene related peptide (CGRP) or its analogs. Renal failure and male impotence can also be treated using CGRP or its analogs. CGRP is a naturally occurring substance in the human body. As such, CGRP does not have the same toxicity and allergy problems as the foreign substances that currently are used for similar purposes. When locally applied or infused, the effects of CGRP are limited to a local vascular area. Virtually no systemic effects are induced, making CGRP extremely safe and effective.

L17 ANSWER 3 OF 10 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.

1999150541 EMBASE The effect of neuropeptides/hormones on Langerhans cells. Torii H.; Tamaki K.; Granstein R.D.. H. Torii, Department of Dermatology, University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-8655, Japan. Journal of Dermatological Science 20/1 (21-28) 1999. Refs: 47.

ISSN: 0973-1811. CODEN: JDSCEI.

Publisher Ident.: S 0973-1811(99)0004-3. Pub. Country: Ireland. Language: English. Summary Language: English.

AB Neuropeptides/hormones have been shown to regulate the various functions of many immunocompetent cells. A number of neuropeptides/hormones has been demonstrated to be present in the skin and a close anatomical association between calcitonin gene-related peptide (CGRP)-containing nerves and Langerhans cells (LC) has been reported. In addition to the CGRP receptor, receptors for several neuropeptides including pituitary adenylate cyclase activating polypeptide (PACAP) and gastrin releasing peptide (GRP) are found in LC, suggesting these neuropeptides might have some effects on LC. CGRP inhibits alloantigen presentation and stimulation of a specific-antigen responsive T-cell clone by LC. Pre-treatment of LC with CGRP also inhibits the elicitation of delayed type hypersensitivity (DTH) in tumor immune mice. Upregulation of B7-1 expression on LC is suppressed by CGRP, which might be, in part, responsible for the inhibitory effect of CGRP in the functional assay. The production of some inflammatory cytokines such as IL-10 by LC-like cell line KS12 is regulated by CGRP and the functional effect of CGRP appears to be at least partially mediated through the autocrine regulation of IL-10. .alpha.-MSH is another neuropeptide, the effect of which has been well studied in the cutaneous immune system. Pre-treatment of mice with .alpha.-MSH produces inhibitory effects in contact hypersensitivity (CHS). IL-10 has been suggested to be involved in the inhibitory effect of .alpha.-MSH. The receptors and the functional effects of other proopiomelanocortin (POMC)-derived peptides including .beta.-endorphin and catecholamines on LC are under investigation.

L17 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2002 ACS

1999:021293 Document No. 139:137184 Polynucleotides that encode the human calcitonin gene-related peptide receptor component factor (CGRP-RP, HOUNDC44). Adamou, John E.; Elshourbagy, Nabil. Smithkline Beecham

Corp., USA). U.S. US 5710024 A 19980120, 24 pp. (English). CODEN: USXXAM. APPLICATION: US 1996-686178 19960723.

AB Human **CGRP**-PCF polypeptides and DNA (RNA) encoding such **CGRP**-PCF and a procedure for producing such polypeptides by recombinant techniques is disclosed. **CGRP**-PCF is obtained using std. cloning and screening procedures, such as those for cloning cDNAs using mRNA from human adipocytes from osteoplastoma as starting material. Human **CGRP**-PCF cDNA contains an open reading frame encoding a protein of 148 amino acid residues, and is structurally related (83% identity and 94% similarity) to the guinea pig **CGRP**-PCF. Procedures are provided for expression and purifn. of human **CGRP**-PCF using recombinant bacteria, cloning and expression in a baculovirus expression system, and gene therapeutic expression in fibroblasts. Also disclosed are methods for utilizing such **CGRP**-PCF for the **treatment** of diabetes, migraine, pain and inflammation, Parkinson's disease, acute heart failure, hypotension, urinary retention, osteoporosis, hypertension, angina pectoris, myocardial infarction, ulcers, asthma, **allergies**, psychosis, depression, vomiting, benign prostatic hypertrophy, Paget's disease, obesity, cancer, gigantism and the like. Antagonists against such **CGRP**-PCF and their use as a therapeutic to treat diabetes, migraine, pain and inflammation, Parkinson's disease, acute heart failure, hypotension, urinary retention, osteoporosis, hypertension, angina pectoris, myocardial infarction, ulcers, asthma, **allergies**, psychosis, depression, vomiting, benign prostatic hypertrophy, Paget's disease, obesity, cancer, gigantism and the like are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered bonds. of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding the **CGRP**-PCF and for detecting altered levels of the polypeptide in a host.

L17 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2002 ACS

1997:643631 Document No. 127:643636 **Treatment** of preeclampsia, eclampsia or preterm labor with calcitonin gene related peptide and related drugs. Yallampalli, Chandrasekhar; Wimalawansa, Sunil J. (Board of Regents, the University of Texas System, USA; Yallampalli, Chandrasekhar; Wimalawansa, Sunil J.). PCT Int. Appl. WO 9734922 A1 19970929, 37 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BE, BG, BR, BY, CA, CH, CN, CU, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AS, BY, KG, KZ, MD, RU, TJ, TM; EW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MF, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: SIXXDE. APPLICATION: WO 1997-054313 19970918. PRIORITY: US 1996-619841 19960319.

AB The present invention provides a method for counteracting preeclampsia, eclampsia of pregnancy and preterm labor in a pregnant female mammal treated by administering thereto calcitonin gene-related peptide (**CGRP**) or its analogs including **CGRP**/adrenomedullin or their peptide or receptor-based analogs, or in combination with a progestin, and with or without a nitric oxide substrate, or a nitric oxide donor or both, optionally in further combination with one or more of a cyclooxygenase inhibitor, a PGI<sub>2</sub>-mimetic, a thromboxane (TXA<sub>2</sub>) inhibitor, a compd. possessing TXA<sub>2</sub>-agonistic, and TXA<sub>2</sub>-inhibiting properties, a compd. possessing TXA<sub>2</sub>-antagonistic and PGI<sub>2</sub>-mimetic activities, and a TXA<sub>2</sub> antagonist. **CGRP**, progesterone and nitric oxide substrate and/or any nitric oxide donor compds., alone or in combination can be used. As **CGRP** is a naturally occurring compd., it does not have the same toxicity and **allergy** problems as the foreign substances that are currently used for similar purposes. During pregnancy uterine blood vessels and the uterine muscles are extremely sensitive to **CGRP** as well as nitric oxide. Therefore, one could administer a very small quantities of these drugs i.e., i.v., s.c., or implants, the



effects are then seen mainly in the uterine muscle and blood vessels, namely increase the blood supply to the utero-placental unit (hence nutrients and oxygen supply to the fetus through the improved placental circulation), and uterine muscular relaxation thereby ameliorate the signs and symptoms of preeclampsia, and eclampsia, and prevent preterm labor. At these dosages, virtually no systemic effects are induced, making **CGRP** (which is an endogenous natural product present in human body) extremely safe and effective.

L17 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2002 ACS

1997:366286 Document No. 126:334212 Cosmetic and pharmaceutical compositions containing salts of lanthanide, tin, zinc, manganese, yttrium, cobalt, strontium as substance P antagonists. Breton, Lionel; De Lacharriere, Olivier (Creal S. A., Fr.). Eur. Pat. Appl. EP 770392 A2 19970502, 10 pp. DESIGNATED STATES: R: AT, BE, CH, DE, ES, FR, GB, IE, IT, LI, NL, SE. (French). CODEN: EEXXDW. APPLICATION: EP 1996-402182 19961014. PRIORITY: FR 1995-12653 19951026.

AB The title cosmetic and pharmaceutical compns. are claimed for **treatment** of disorders assocd. with excess synthesis or release of substance P. A lotion contained manganese chloride 15.00, glycerol 2.00, Me paraben 0.15, perfume q.s., and water q.s. 100.00.

L17 ANSWER 7 OF 10 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.

97231534 EMBASE Document No.: 1997231534. Calcitonin gene-related peptide and Langerhans cell function. Torii H.; Hosoi J.; Asahina A.; Granstein R.D.. Dr. R.D. Granstein, Department of Dermatology, Cornell University Medical College, 525 East 68th Street, New York, NY 10021, United States. Journal of Investigative Dermatology Symposium Proceedings 2/1 (52-86) 1997. Refs: 37.

ISSN: 1087-8024. CODEN: JDSPEO. Pub. Country: United States. Language: English. Summary Language: English.

AB Morphologic studies have indicated that Langerhans cells (LC) are frequently in anatomic apposition with epidermal nerves containing the neuropeptide calcitonin gene-related peptide (**CGRP**). Experiments were undertaken to examine whether **CGRP** modulates LC function. The effect of pre-exposure of LC to **CGRP** in vitro on all-antigen presentation and specific protein presentation to a responsive T-cell line were studied using freshly prepared murine epidermal cell populations enriched for LC content (EC) by **treatment** with antibody to Thy-1 and complement. The ability of EC to present tumor-associated antigens for induction and elicitation of delayed-type hypersensitivity (DTH) in tumor-immune mice was also examined. Inhibitory effects of **CGRP** on antigen presentation were observed in each of these assays. Experiments were also performed examining the ability of intradermally administered **CGRP** to modulate induction of contact hypersensitivity (CHS) to a hapten applied at the injected site. Administration of **CGRP** led to a decrease in the CHS response after immunization at the site of injection. Intracellular cAMP was significantly increased in freshly prepared LC after exposure to **CGRP**, and this process could be inhibited by a specific inhibitor of the **CGRP** receptor, demonstrating the existence of **CGRP** receptors on LC. B7-2 expression induced by LPS and GM-CSF in the LC-like line XS12, and by LPS in peritoneal macrophages, was suppressed by **CGRP**. This suppression may account, in part, for the inhibitory effect of **CGRP**. As a whole, these observations suggest that regulation of antigen presentation by nerves may occur in the epidermis.

L17 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2002 ACS

1996:666996 Document No. 125:284978 Use of a calcitonin gene-related peptide antagonists for the **treatment** of ocular or eyelid pruritus and dysesthesia. De Lacharriere, Olivier; Breton, Lionel (Creal S. A., Fr.). Eur. Pat. Appl. EP 734730 A1 19961002, 9 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE. (French).

CODEN: EPKXLDW. APPLICATION: EP 1996-400459 19960304. PRIORITY: FR 1995-3629 19950323.

AB Pharmaceutical or cosmetic compns. contg. calcitonin gene-related peptide (CGRP) antagonists are used for the **treatment** of ocular or eyelid pruritus and dysesthesia. A collyrium contained CGRP 8-87 0.5, and excipients comprising sodium chloride, sodium borate, Polysorbate 80, boric acid and water q.s. 100%.

L17 ANSWER 2 OF 10 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.

91101225 EMBASE Document No.: 1991101225. Airways vasodilatation in the immediate allergic reaction. Involvement of inflammatory mediators and sensory nerves. Alving K. Department of Pharmacology, Karolinska Institutet, S-104 01 Stockholm, Sweden. Acta Physiologica Scandinavica, Supplement 141/597 (1-64) 1991. ISSN: 0001-2994. CODEN: APSSAD. Pub. Country: United Kingdom. Language: English. Summary Language: English.

AB 1. Systemic capsaicin **treatment** of the pig depletes the content of sensory neuropeptides (CGRP and tachykinins) in the airways mucosa and skin, without affecting sympathetic and parasympathetic nerves containing NEY and VIS, or the presence and appearance of inflammatory cells including mast cells. Acute capsaicin exposure caused release of sensory neuropeptides and catecholamines, and marked vasodilatation in the airways and skin, without signs of plasma protein extravasation or bronchoconstriction. Capsaicin pretreatment effectively desensitizes against local challenges with capsaicin in the airways and skin, as revealed by the absence of vasodilatory responses 2 days later. 2. Cigarette smoke exposure induces marked vasodilatation, lasting for about 5 min in both the upper and lower airways, which seems not to be primarily caused by particulate matter or nicotine in the smoke. Except for a minor capsaicin-sensitive component in the nasal circulation, these responses probably do not involve neural activation, mast cell degranulation or prostaglandin formation. Rather, it is concluded that vapour phase components act on the vessels via unknown mechanisms. 3. Sensitization of pigs with s.c. injections of ascaris antigen was successful, resulting in typical wheal and flare reactions in the skin and bronchoconstriction after local challenge with antigen. The reactivity to ascaris is probably mediated by antibodies of the IgE isotype. 4. Histamine-containing mast cells and sensory neuropeptide-containing nerve fibres show close morphological association around blood vessels in the pig skin. Both alcian blue-positive mast cells and capsaicin-sensitive sensory nerves are present close to the pig airways epithelium. Sensory neuropeptide-containing nerves are also abundant around airways mucosal blood vessels, whereas the bronchial smooth muscle is sparsely innervated. 5. Allergen and histamine injections in the skin caused similar responses consisting of flare and protein extravasation. Allergen challenge in the airways induces marked vasodilatation lasting for 60-90 min in the pig bronchial and nasal circulations. Histamine seems to be important in the early phase (0-20 min) of these responses in the airways, while cyclo-oxygenase products (possibly PGD<sub>2</sub>) may be responsible for the long-lasting component. A cyclo-oxygenase product is presumably also released from the lung into the circulation after bronchial allergen challenge and thereby induces a delayed, long-lasting nasal vasodilatation. Histamine may be the main bronchoconstrictor agent released in the immediate allergic reaction of the pig. 6. The flare, but not the protein extravasation reaction, to allergen and histamine injections in the skin, was inhibited by capsaicin pretreatment. Aerosolized histamine and bradykinin, but not PGD<sub>2</sub>, seem to cause airways vasodilatation partly via activation of capsaicin-sensitive sensory nerves. Nedocromil sodium reduces the airways vasodilatation response to bradykinin and the histamine-induced nasal vasodilatation in the same manner as capsaicin pretreatment. It may thus be suggested that nedocromil sodium acts at least partly by inhibiting sensory nerve activation by inflammatory mediators. Nedocromil sodium also reduced the allergen-induced bronchoconstriction, indicating an inhibitory action on

mast cells as well. Capsaicin-sensitive sensory nerves are probably mainly involved in the airways vasodilatation seen after allergen challenge. 7. In conclusion, a large animal model has been developed where the influence of irritants and allergen on arterial blood flow at three different levels of the airways can be monitored in parallel to pulmonary mechanics. Furthermore, by using systemic capsaicin pretreatment, the involvement of capsaicin-sensitive sensory nerves in airways reactions can be studied. The pig seems to be more related to man, regarding sensory nerve-mediated protein extravasation and bronchoconstriction, compared to the rat and guinea pig. The airways vasodilatation in the immediate allergic reaction may primarily involve histamine and EGD2. Part of the response is probably mediated via activation of capsaicin-sensitive sensory nerves by mediators such as histamine and bradykinin. Cigarette smoke-induced vasodilatation may be caused by vapour phase components acting on the vessels.

L17 ANSWER 10 OF 10 MEDLINE DUPLICATE 1  
 87182279 Document Number: 87182279. PubMed ID: 3494409.  
 Capsaicin-sensitive nerves and the cutaneous **allergy** reaction in man. Possible involvement of sensory neuropeptides in the flare reaction. Lundblad L; Lundberg J M; Anggard A; Zetterstrom O. ALLERGY, (1987 Jan) 42 (1) 20-5. Journal code: 7804028. ISSN: 0105-4538. Pub. country: Denmark. Language: English.

AB The effects of local capsaicin pretreatment on the cutaneous triple response reaction induced by allergen exposure or anti-IgE were studied in man. Acute exposure of the human skin to capsaicin caused a burning sensation and a clearcut flare reaction but no wheal response. Upon repeated administration these local reactions to capsaicin disappeared. The flare component and the subjective itching sensation of the cutaneous **allergy** reaction to rat antigen in sensitized persons or anti-IgE in non-allergic persons were then markedly reduced. Two weeks after capsaicin pretreatment the flare response to allergen was not significantly changed compared to the control reaction, suggesting a reversible effect of capsaicin **treatment**. The wheal component of the **allergy** or anti-IgE reaction was, however, not influenced by capsaicin pretreatment, indicating that the wheal and flare components are caused by different mechanisms. It is concluded that capsaicin sensitive sensory nerves are of importance for the human cutaneous triple response reaction induced by allergen exposure. Thus, secondary release of mediators, such as **CGRP** or tachykinins from sensory nerve branches, may contribute to the flare component of this reaction. Furthermore the itching sensation seems to be dependent to a large extent on capsaicin-sensitive nerves. However, sensory nerves seem to have less importance for the wheal reaction, i.e. the protein extravasation response.

=>

=>

Executing the logoff script...

=> LOG H

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	77.78	77.97
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-5.98	-5.98

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 13:02:59 ON 20 JUL 2002